Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021749 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
A Phase 1 study of Chronic Lymphocytic Leukemia and CLL, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00021749 is a Phase 1 study of Chronic Lymphocytic Leukemia and CLL that has completed, run by Genta Incorporated. The registered enrollment target is 40 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00021749, a Phase 1 study of Chronic Lymphocytic Leukemia and CLL, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
Conditions Studied
Interventions
- DRUG Oblimerson sodium, G3139
Study Locations (3)
Texas
- MD Anderson Cancer Center - Houston
- San Antonio Cancer Institute - San Antonio
New York
- Long Island Jewish Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021749
The ClinicalTrials.gov registry entry for NCT00021749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Oblimerson sodium, G3139 is the first listed.
NCT00021749 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, New York.
Frequently Asked Questions
What is clinical trial NCT00021749 about?
NCT00021749 is a clinical study titled "Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia". This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
What is the current status of trial NCT00021749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2001-01.
What conditions does trial NCT00021749 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, CLL.
What interventions are being tested in trial NCT00021749?
The interventions under investigation include: Oblimerson sodium, G3139 (DRUG).
Who is sponsoring clinical trial NCT00021749?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021749 being conducted?
This trial has 3 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.